Overview

* AbCellera Q3 2025 revenue rises to $9 mln, beating analyst expectations

* Net loss widens to $57.1 mln, driven by higher R&D expenses

* Company advances two lead programs through Phase 1 clinical trials

Result Drivers

* R&D INVESTMENTS - Increased R&D expenses focused on internal programs, including $15 mln investment in two lead programs

* LIQUIDITY MANAGEMENT - Maintained $680 mln in available liquidity to support strategic execution

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $9 mln $5.91

Revenue mln (8

Analysts

)

Q3 Net -$57.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Abcellera Biologics Inc ( ABCL ) is $8.50, about 44.8% above its November 5 closing price of $4.69

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)